Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 1, 2015, Pages 197-204

  Feng, Q ^a   Huang, Y ^a   Chen, M ^b   Li, G ^a   Chen, Y ^a  

^a JILIN UNIVERSITY   (China)

^b Changchun Weresai Biotech Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MICE, INBRED ICR; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84920077875     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2219-3     Document Type: Article

References (36)

1. Troillet N, Samore MH, Carmeli Y (1997) Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 25:1094–1098
2. Hardin TC, Jennings TS (1994) Cefepime. Pharmacotherapy 14:657–668
3. Davis R, Bryson HM (1994) Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47:677–700
4. Ge M, Chen Z, Onishi HR, Kohler J, Silver LL, Kerns R, Fukuzawa S, Thompson C, Kahne D (1999) Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 284:507–511
5. Fernandes P (2006) Antibacterial discovery and development—the failure of success? Nat Biotechnol 24:1497–1503
6. Safdar N, Handelsman J, Maki DG (2004) Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 4:519–527
7. Spiegel CA (1988) Laboratory detection of high-level aminoglycoside-aminocyclitol resistance in Enterococcus spp. J Clin Microbiol 26:2270–2274
8. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41:149–158
9. Hirano L, Bayer AS (1991) Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother 35:685–690
10. Grindey GB, Nichol CA (1972) Interaction of drugs inhibiting different steps in the synthesis of DNA. Cancer Res 32:527–531
11. Cirioni O, Ghiselli R, Orlando F, Silvestri C, Mocchegiani F, Rocchi M, Chiodi L, Abbruzzetti A, Saba V, Scalise G, Giacometti A (2007) Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit Care Med 35:1717–1723
12. De Clercq E (2004) Antiviral drugs in current clinical use. J Clin Virol 30:115–133
13. Cirioni O, Giacometti A, Ghiselli R, Kamysz W, Orlando F, Mocchegiani F, Silvestri C, Licci A, Chiodi L, Lukasiak J, Saba V, Scalise G (2006) Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 27:1210–1216
14. Hancock RE, Chapple DS (1999) Peptide antibiotics. Antimicrob Agents Chemother 43:1317–1323
15. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389–395
16. Chen Y, Guarnieri MT, Vasil AI, Vasil ML, Mant CT, Hodges RS (2007) Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrob Agents Chemother 51:1398–1406
17. Hancock RE (1998) The therapeutic potential of cationic peptides. Expert Opin Investig Drugs 7:167–174
18. Marr AK, Gooderham WJ, Hancock RE (2006) Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 6:468–472
19. Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML, Hodges RS (2005) Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J Biol Chem 280:12316–12329
20. Pillai SK, Moellering R, Eliopoulos GM (2005) Antimicrobial combinations. Antibiot Lab Med 5:365–440
21. Petersen PJ, Labthavikul P, Jones CH, Bradford PA (2006) In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time–kill kinetic analysis. J Antimicrob Chemother 57:573–576
22. Wiegand I, Hilpert K, Hancock RE (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3:163–175
23. Zhu L-W, Shi L-M, Jiang J-X, Yang Z-K, Chen P (2008) Studies on Antibacterial Properties of the Natural Bamboo Fabric Based on FZ/T 73023—2006 [J]. J Donghua Univ (Nat Sci) 4:005
24. Zhang L, Benz R, Hancock RE (1999) Influence of proline residues on the antibacterial and synergistic activities of alpha-helical peptides. Biochemistry 38:8102–8111
25. Zhang L, Falla T, Wu M, Fidai S, Burian J, Kay W, Hancock RE (1998) Determinants of recombinant production of antimicrobial cationic peptides and creation of peptide variants in bacteria. Biochem Biophys Res Commun 247:674–680
26. Zhao LJ, Huang YB, Gao S, Cui Y, He D, Wang L, Chen YX (2013) Comparison on effect of hydrophobicity on the antibacterial and antifungal activities of α-helical antimicrobial peptides. Science China (Chemistry) 56:1307–1314
27. Hong SY, Oh JE, Lee KH (1999) Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol 58:1775–1780
28. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, Dunn DL, Kreter B (1999) Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 44:263–273
29. Ehrenstein G, Lecar H (1977) Electrically gated ionic channels in lipid bilayers. Q Rev Biophys 10:1–34
30. Andersson DI (2003) Persistence of antibiotic resistant bacteria. Curr Opin Microbiol 6:452–456
31. Davies J (1994) Inactivation of antibiotics and the dissemination of resistance genes. Science 264:375–382
32. Livermore DM (2003) Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36:S11–S23
33. Mataraci E, Dosler S (2012) In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother 56:6366–6371
34. Jenssen H, Hamill P, Hancock RE (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19:491–511
35. Shai Y (1999) Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1462:55–70
36. Chen Y, Vasil AI, Rehaume L, Mant CT, Burns JL, Vasil ML, Hancock RE, Hodges RS (2006) Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chem Biol Drug Des 67:162–173